Jnana pharmaceuticals
WebBOSTON, Mass., November 15, 2024 – Jnana Therapeutics (“Jnana”), a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines … Web15 nov. 2024 · Jnana Therapeutics is a clinical-stage biotechnology company leveraging its next-generation chemoproteomics RAPID platform to discover medicines for highly …
Jnana pharmaceuticals
Did you know?
Web16 mrt. 2024 · Jnana’s RAPID platform allows us to systematically develop small molecule medicines for any target class with unmatched speed and efficiency. Together, we are … The team at Jnana Therapeutics is driven by a shared purpose to deliver … Stay up to date with Jnana on the latest biotechnology news and presentations. … Jnana Therapeutics Inc. One Design Center Place Suite 19-400 Boston, MA 02210 BOSTON, Mass., April 26, 2024 – Jnana Therapeutics, a biotechnology company … Heather brings over 18 years of drug discovery experience to Jnana working … Web2 nov. 2024 · Barrish joined Jnana from Achillion Pharmaceuticals, where he served as Chief Scientific Officer. ... Jnana is focused on developing best-in-class therapies to treat …
Web3 feb. 2024 · He joins Jnana from Momenta Pharmaceuticals, where he led Financial Planning & Analysis. Previously, he served for more than 20 years in roles of increasing responsibility at Sanofi Genzyme. Web15 nov. 2024 · Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, today …
WebJnana's wholly owned lead program is a potential first-in-class oral approach, targeting an allosteric site on the phenylalanine transporter SLC6A19, for the treatment of phenylketonuria (PKU), a ... Web26 apr. 2024 · Jnana Therapeutics is a biotechnology company utilizing their RAPID platform to address well-validated but hard-to-drug targets. Jnana is focused on developing first- and best-in-class...
Web15 nov. 2024 · Jnana Therapeutics is a clinical-stage biotechnology company leveraging its next-generation chemoproteomics RAPID platform to discover medicines for highly …
Web15 nov. 2024 · Jnana initiates Phase 1 clinical trial of JNT-517, a potential first-in-class oral treatment for PKU; JNT-517 receives US FDA Rare Pediatric Disease Designation; ... echo heart xthoracic limitedecho heart testingWeb13 mrt. 2024 · Results. The mean ± standard deviation age was 78 ± 6 years; the mean eGFRcys, eGFRcr, and eGFRcr-cys concentrations were 59 ± 23, 64 ± 20, and 61 ± 22 mL/min/1.73 m 2, respectively, and the mean mGFR concentration was 56 ± 19 mL/min. Half of the participants were in the lower eGFRcys group (n=337, 51%). Among them, … compression molded uhmwWeb3 feb. 2024 · BOSTON--(BUSINESS WIRE)--Jnana Therapeutics, a biotechnology company targeting the solute carrier (SLC) family of metabolite transporters to treat underserved … compression molded waxWebJnana Therapeutics is a clinical-stage biotechnology company leveraging its next-generation chemoproteomics RAPID platform to discover medicines for highly validated, … compression molded pvc floatsWeb14 dec. 2024 · Jnana Therapeutics @jnanatx · Nov 2, 2024 We’re applying our RAPID platform to address hard-to-drug targets including SLC transporters, scaffold proteins, transcription factors, phosphatases, and helicases. ow.ly/g9PM50GE9Hk Jnana Therapeutics @jnanatx · Nov 2, 2024 compression molded rubber partsWeb10 okt. 2024 · IONIS-FB-LRx, an antisense drug using Ionis' advanced LIgand Conjugated Antisense (LICA) technology, reduces the production of FB, a key protein in the complement innate immune system. FB is predominately produced in the liver and circulates throughout the vascular system, including vessels in the eye and kidney. echoheat lining